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Background/Aims: To determine factors predictive of dis-
cordance in staging liver fibrosis using liver biopsy (LB) and 
acoustic radiation force impulse (ARFI) elastography in pa-
tients with chronic hepatitis B (CHB). Methods: Consecutive 
patients with CHB who underwent LB and ARFI elastography 
on the same day from November 2010 to March 2013 were 
prospectively recruited from three tertiary hospitals. Results: 
We analyzed 105 patients (median age of 47 years). The F0–1, 
F2, F3, and F4 fibrosis stages were identified in 27 (25.7%), 
27 (25.7%), 21 (20.0%), and 30 (28.6%) patients, respec-
tively. The areas under the receiver operating characteristics 
curves for ARFI elastography in assessing ≥F2, ≥F3, and F4 
was 0.814, 0.848, and 0.752, respectively. The discordance 
of at least one stage between LB and ARFI was observed in 
68 patients (64.8%) and of at least two stages in 16 patients 
(15.2%). In a multivariate analysis, advanced fibrosis stage 
(F3–4) was the only factor that was negatively correlated 
with one-stage discordance (p=0.042). Moreover, advanced 
fibrosis stage was negatively (p=0.016) correlated and body 
mass index (BMI) was positively (p=0.006) correlated with 
two-stage discordance. Conclusions: Advanced fibrosis stage 
(F3–4) was a predictor of nondiscordance between LB and 
ARFI elastography; BMI also influenced the accuracy of ARFI 
elastography. (Gut Liver 2016;10:275-282)
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INTRODUCTION
Since the prognosis and treatment strategy for patients with 
chronic liver disease (CLD) are closely related to the degree of 
fibrosis, assessment of liver fibrosis is important in patients with 
CLD.1 Until now, liver biopsy (LB) has been considered the gold 
standard for assessing liver fibrosis;2 however, its use is limited 
because of its invasiveness, risk of complications, sampling er-
ror,3,4 and interpretational variability.5 In addition, these factors 
make sequential LBs impractical, especially when repeated ex-
aminations are required to monitor response to antiviral or anti-
fibrotic treatment. All of these issues have encouraged research 
into noninvasive approaches. As a results, several noninvasive 
surrogates for LB have been introduced for the assessment of 
liver fibrosis: transient elastography (TE) (Fibroscan®; EchoSens, 
Paris, France),6-8 acoustic radiation force impulse elastography 
(ARFI elastography, Acuson S20000; Siemens Medical Solu-
tions, Mountain View, CA, USA),9 and several serum fibrosis 
prediction indices.10
After vigorous validation, liver stiffness (LS) measurement us-
ing TE has become a widely applied procedure for assessing the 
severity of liver fibrosis.6 Furthermore, LS measurement using 
TE can be used to select treatment strategies, predict prognosis, 
and monitor disease progression. However, unsatisfactory TE 
performance has been reported for patients with ascites, a nar-
row intercostal space, or obesity.11,12 In addition, necroinflam-
matory activity, as indicated by a high alanine aminotransferase 
(ALT) level, is the single most important confounder and has 
been known to diminish the accuracy of LS measurement using 
TE.13,14 
Recently, ARFI elastography, which uses radiation-forced im-
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pulses to measure LS while using B-mode ultrasonography, was 
also introduced.15 In contrast to TE which has a fixed region 
of interest (ROI) at a fixed insertion depth, ARFI elastography 
has a flexible ROI at variable depths which enables LS mea-
surement in patients with ascites and obesity.16-18 Furthermore, 
ARFI elastography has another advantage in that it enables LS 
measurement during a routine ultrasonographic evaluation of 
the abdomen. The ease of this study facilitates sequential LS 
measurements during routine outpatient visits for follow-up.19 
However, most investigations on ARFI elastography have been 
performed in European patients with chronic hepatitis C (CHC), 
whereas few studies are available that used Asian populations, 
where chronic hepatitis B (CHB) infection is endemic.15 Further-
more, it has not been determined yet which factors influence 
the accuracy of ARFI elastography in Asian patients with CHB. 
Necessarily, noninvasive surrogates for LB, including ARFI elas-
tography, are always subject to discordance compared to the 
histologic staging of fibrosis. Thus, a study of factors associated 
with discordance between noninvasive surrogates and LB could 
enable us to more effectively use noninvasive methods.
Hence, we investigated the diagnostic performance of ARFI 
elastography in assessing different degrees of liver fibrosis in 
patients with CHB from three Korean tertiary hospitals. We fur-
ther identified factors that influence the accuracy of ARFI elas-
tography by investigating which factor is related to discordant 
LB and ARFI elastography results in staging liver fibrosis.
MATERIALS AND METHODS
1. Patients
From November 2010 to March 2013, consecutive patients 
with CHB who underwent both LB and LS measurement using 
ARFI elastography on the same day at three tertiary hospitals 
of Shinchon Severance Hospital, Seoul, Kyungpook National 
University Hospital, Daegu, and Pusan National University 
Yangsan Hospital, Yangsan, Korea were prospectively recruited 
for this study. CHB was defined as the persistent presence of 
serum hepatitis B virus surface antigen (HBsAg) for more than 6 
months. LB was performed to assess the severity of fibrosis prior 
to antiviral treatment.
The exclusion criteria were as follows: a history of hepatocel-
lular carcinoma or other malignancy at the time of LB, a LB 
specimen shorter that 10 mm, co-infection with HIV or hepatitis 
C or hepatitis D virus, alcohol ingestion in excess of 40 g/day 
for more than 5 years, LB and ARFI elastography performed 
on different days, Child-Pugh classification B or C, evidence of 
decompensated liver cirrhosis, including a history of variceal 
bleeding, ascites, hepatic encephalopathy, or a previous history 
of antiviral therapy (Supplementary Fig. 1).
The study was performed in accordance with the ethical 
guidelines of the 1975 Declaration of Helsinki. Written informed 
consent was obtained from each participant or responsible 
family member after detailed explanation of the study and pos-
sible complications of the diagnostic procedures had been fully 
explained. This study was approved by the Institutional Review 
Board of each hospital.
2. Clinical data
Demographic details and body mass index (BMI) were col-
lected. The following laboratory data were also collected from 
all patients at the time of LB and ARFI elastography: serum 
total cholesterol, serum albumin, total bilirubin, aspartate ami-
notransferase (AST), ALT, prothrombin time, and platelet count. 
HBsAg and hepatitis B e antigen were measured using standard 
enzyme-linked immunosorbent assays (Abbott Diagnostics, 
Abbott Park, IL, USA at Shinchon Severance Hospital, Roche 
Modular E170, Roche Diagnostics GmbH, Mannheim, Germany 
at Kyungpook National University Hospital, and Bio Focus 
Co., Ltd., Uiwang, Korea at Pusan National University Yangsan 
Hospital). Hepatitis B virus (HBV) DNA levels were measured by 
quantitative polymerase chain reaction assay (Amplicor HBV 
Monitor Test; Roche Diagnostics, Basel, Switzerland; detection 
limit approximately 12 IU/mL at Shinchon Severance Hospi-
tal and Kyungpook National University Hospital and Abbott 
m2000, Abbott Molecular Inc., Des Plaines, IL, USA; detection 
limit 10 IU/mL at Pusan National University Yangsan Hospital). 
3. LS measurement using ARFI elastography
For all patients, ARFI elastography was performed on the 
same day as LB by a single physician at each hospital (all 
physicians had more than 2 years of experience with ultraso-
nography and more than 300 examinations with ARFI elastog-
raphy). The physicians were blinded with regard to the clinical 
and biochemical data of each patient. Details of the technical 
background and examination procedure have been described 
previously.20,21 Briefly, while performing a real time B-mode 
imaging, a 10×5-mm ROI was placed over vessel-free liver 
parenchyma. Tissue in the ROI was excited by short-duration 
acoustic pulses to generate localized tissue displacement, which 
resulted in shear-wave propagation away from the region of 
excitation. Shear-wave propagation was tracked using ultraso-
nography correlation-based methods. The shear-wave velocity 
can be reproduced by measuring the time to peak displacement 
at each location, and the shear-wave velocity of the tissue is 
proportional to the square root of tissue elasticity. All measure-
ments were performed on the right hepatic lobe, using an inter-
costal view with breath-holding technique. In each patient, LS 
was measured 1 to 3 cm below the liver capsule based on the 
previous study.17 To ensure quality of measurement, more than 
10 successful acquisitions in each patient were performed and 
mean value was considered to represent the elastic modulus of 
the liver.15 Results were expressed as meters per second (m/sec). 
The interquartile range (IQR) was defined as an index of the LS 
values’ intrinsic variability and corresponded to the 25th and 
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75th percentile intervals around the LS result containing 50% of 
the valid measurements.
4. LB examination
Percutaneous LB was performed using a 16- to 18-gauge 
disposable needle immediately after ARFI elastography. Before 
performing LB, we examined target liver parenchyma for bi-
opsy and obtained ARFI values. Then, LB was performed. The 
LB specimens were fixed in formalin and embedded in paraffin. 
Sections 4 μm thick were stained with hematoxylin and eosin 
and Masson’s trichrome. All tissue samples were evaluated by 
an experienced hepatopathologist at each institute who was 
blinded to the patients’ clinical data including LS results. Liver 
histology was evaluated semiquantitatively according to the 
Batts and Ludwig scoring system.22 Fibrosis was staged on a 0–4 
scale: F0, no fibrosis; F1, portal fibrosis; F2, periportal fibrosis; 
F3, septal fibrosis; and F4, cirrhosis. Significant fibrosis was de-
fined as stage F2 or greater, advanced fibrosis as F3 or greater, 
and cirrhosis as F4.
5. Definitions of discordance between LB and ARFI elastog-
raphy
To define discordance between LB and ARFI elastography, 
the external ARFI cutoff values for staging liver fibrosis were 
adopted from a previous Korean study.15 Cutoff values were 1.13 
m/sec for significant fibrosis (≥F2), 1.50 m/sec for advanced 
fibrosis (≥F3) which was calculated from the same cohort,15 and 
1.98 m/sec for cirrhosis (F4). Based on these external cutoff 
values and previous studies,23,24 discordance was defined as a 
discordance between fibrosis stages determined by ARFI elas-
tography and LB of one or two stages.
6. Statistical analysis
Patient characteristics are reported as medians (ranges) or n 
(%), as appropriate. The independent t-test or Mann-Whitney U 
test was used to compare continuous variables. The chi-square 
test or Fischer exact test was used to compare categorical vari-
ables. Receiver operating characteristics (ROC) curves and areas 
under the ROC curves (AUROCs) were used to estimate diagnos-
tic performance. Optimal internal cutoff values were calculated 
that maximized sensitivity (Se) and specificity (Sp). Positive 
and negative predictive values (PPV and NPV) and positive and 
negative likelihood ratios were also computed. Univariate and 
multivariate binary logistic regression analyses were performed 
to identify independent factors related to discordance between 
LB and LS measurement by ARFI elastography. A p-value <0.05 
was considered statistically significant. The only variables which 
were significant in univariate analysis (p<0.05) could be used 
for multivariate analysis. The statistical analysis was performed 
using SPSS software version 18.0 (SPSS Inc., Chicago, IL, USA).
RESULTS 
1. Baseline characteristics
After excluding 19 patients according to predefined exclusion 
criteria, a total of 105 patients were included in the final analy-
sis. The baseline characteristics of the study population are listed 
in Table 1. The median age was 47 years (range, 19 to 82 years) 
and male gender predominated (n=73, 69.5%). The median BMI 
was 23.4 kg/m2 and the median AST and ALT levels were 39 IU/
L and 46 IU/L, respectively. The mean and median ARFI veloci-
ties were 1.89 m/sec and 1.59 m/sec, respectively. The median 
IQR was 0.35 m/sec, the IQR/median 0.24, and the IQR/mean 
0.24.
2. Liver histology and corresponding ARFI velocity 
The histologic fibrosis stages and corresponding ARFI veloci-
ties are summarized in Supplementary Table 1. The proportions 
of patients with fibrosis stages F0–1, F2, F3, and F4 were 25.7% 
(n=27), 25.7% (n=27), 20.0% (n=21), and 28.6% (n=30), respec-
tively. The mean ARFI velocity of each fibrosis stage were 1.38 
m/sec for F0–1, 1.61 m/sec for F2, 2.17 m/sec for F3, and 2.40 
m/sec for F4. The mean ARFI velocity tended to increase as fi-
brosis stage increased (p<0.05 for F0–1 vs F2 and F2 vs F3), but 
there was no significant difference between stage F3 and stage 
F4 (p=0.429) (Fig. 1).
Table 1. Baseline Characteristics (n=105)
Variable Value
Demographic data
    Age, yr 47 (19–82)
    Male gender 73 (69.5)
    Body mass index, kg/m2 23.4 (16.1–35.7)
Laboratory data
    Total cholesterol, mg/dL 165 (109–265)
    Serum albumin, g/dL 4.3 (3.0–5.4)
    Total bilirubin, mg/dL 0.7 (0.2–2.0)
    Aspartate aminotransferase, IU/L 39 (9–945)
    Alanine aminotransferase, IU/L 46 (4–489)
    Prothrombin time, INR 1.00 (0.88–1.17)
    Platelet count, 109/L 182 (104–333)
    HBV DNA, IU/L 651.25 (0.02–170,000)
    HBeAg positivity 59 (56.2)
ARFI velocity
    Mean, m/sec 1.89±0.84 
    Median, m/sec 1.59±0.52
    Interquartile range, m/sec 0.35 (0.09–2.40)
    Interquartile range/median 0.24 (0.06–1.47)
    Interquartile range/mean 0.24 (0.06–1.34)
Data are presented as median (range), number (%), or mean±SD.
INR, international normalized ratio; HBV, hepatitis B virus; HBeAg, 
hepatitis B e antigen; ARFI, acoustic radiation force impulse.
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3. Prevalence of discordance between LB and ARFI velocity 
Using discriminant external cutoff values which were sug-
gested in a previous study,15 a discordance of at least one stage 
(gray colored) between LB and ARFI velocity was observed in 
68 patients (64.8%) and at least two stages (dark gray colored) 
were observed in 16 patients (15.2%) (Table 2). As a whole, 
fibrosis stage was underestimated in 16 patients (15.2%) and 
overestimated in 52 patients (49.5%) by ARFI elastography in 
comparison to LB (Table 2).
4. Diagnostic performance of ARFI elastography and optimal 
cutoff values
With regard to the diagnostic performance of ARFI elastogra-
phy in predicting histologic liver fibrosis, the AUROC was 0.814 
(95% confidence interval [CI], 0.729 to 0.900) for significant 
fibrosis (≥F2) (Fig. 2A), 0.848 (95% CI, 0.773 to 0.923) for ad-
vanced fibrosis (≥F3) (Fig. 2B), and 0.752 (95% CI, 0.656 to 0.849) 
for cirrhosis (F4) (Fig. 2C), respectively. The optimal internal 
cutoff values to predict fibrosis stage using ARFI elastography 
were 1.31 m/sec for ≥F2 (Se, 89.7%; Sp, 63.0%; PPV, 94.9%; 
NPV, 22.2%), 1.81 m/sec for ≥F3 (Se, 78.4%; Sp, 78.8%; PPV, 
90.2%; NPV, 53.7%), and 1.98 m/sec for F4 (Se, 66.7%; Sp, 
73.3%; PPV, 66.7%; NPV, 73.3%), respectively (Supplementary 
Table 2).
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Fig. 1. Box plots of acoustic radiation force impulse (ARFI) velocity 
in each fibrosis stage. There were statistically significant differences 
in ARFI velocity between stage F0–1 versus F2 and stage F2 versus 
F3 (p=0.030 and p<0.001, respectively), whereas no significant differ-
ence was identified between stage F3 versus F4 (p=0.429). 
Table 2. Distribution of the Fibrosis Stages according to the Histology and External Cutoff of Acoustic Radiation Force Impulse Velocity
Fibrosis stage  
estimated by  
histology
Fibrosis stage estimated by ARFI velocity
F0–1 F2 F3 F4
ARFI<1.13 m/sec 1.13 m/sec≤ARFI<1.50 m/sec 1.50 m/sec≤ARFI<1.98 m/sec ARFI≥1.98 m/sec
F0–1 (n=27) 6 13 7 1
F2 (n=27) 3 7 12 5
F3 (n=21) 1 2 4 14
F4 (n=30) 0 2 8 20
Total (n=105) 10 24 31 40
Gray color, subjects with one-stage discordance in the fibrosis stage as assessed using histology and ARFI velocity; Dark gray color, subjects with 
two-stage discordance in the fibrosis stage as assessed using histology and ARFI velocity.
ARFI, acoustic radiation force impulse.
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Fig. 2. Receiver operating characteristic (ROC) curves for acoustic radiation force impulse values in diagnosing significant fibrosis (≥F2) (A), ad-
vanced fibrosis (≥F3) (B), and cirrhosis (F4) (C). The areas under the ROC curves were 0.814 (95% confidence interval [CI], 0.729 to 0.900) for sig-
nificant fibrosis (≥F2), 0.848 (95% CI, 0.773 to 0.923) for advanced fibrosis (≥F3), and 0.752 (95% CI, 0.656 to 0.849) for cirrhosis (F4).
AUROC, areas under the ROC curve.
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5. Factors affecting the discordance between histology and 
ARFI velocity
On univariate analysis, advanced fibrosis stage (F3–4) was 
the only significant factor negatively associated with one-stage 
discordance between LB and ARFI velocity (p=0.042; odds ratio, 
0.426; 95% CI, 0.187 to 0.969) (Table 3). The one-stage discor-
dance rate was significantly lower in patients with stages F3–4 
than in those with stages F0–2 (52.9% vs 75.9%, respectively; 
odds ratio, 0.426; 95% CI, 0.187 to 0.969; p=0.040) (Fig. 3A).
Univariate analysis showed that BMI and advanced fibrosis 
stage (F3–4) were significant factors affecting two-stage discor-
dance (all p<0.05) and subsequent multivariate analysis showed 
that both BMI and advanced fibrosis stage (F3–4) were statisti-
Table 3. Factors Affecting Discordance in Fibrosis Staging between Histology and Acoustic Radiation Force Impulse Velocity
Variable
One-stage discordance (n=68, 64.8%) Two-stage discordance (n=16, 15.2%)
Univariate Univariate Multivariate
p-value OR (95% CI) p-value p-value OR (95% CI)
Clinical data
    Age, yr 0.613 - 0.422 - -
    Male gender 0.229 - 0.276 - -
    Body mass index, kg/m2 0.998 - 0.002 0.006 1.291 (1.075–1.551)
    Total cholesterol, mg/dL 0.505 - 0.916 - -
    Serum albumin, g/dL 0.335 - 0.247 - -
    Total bilirubin, mg/dL 0.324 - 0.378 - -
    Aspartate aminotransferase, IU/L 0.084 - 0.181 - -
    Alanine aminotransferase, IU/L 0.129 - 0.923 - -
    Prothrombin time, INR 0.995 - 0.739 - -
    Platelet count, 109/L 0.479 - 0.358 - -
    HBV DNA, IU/L 0.246 - 0.716 - -
    HBeAg positivity 0.185 - 0.438 - -
Histological data
    F3–4 (vs F0–2) 0.042 0.426 (0.187–0.969) 0.016 0.016 0.181 (0.045–0.730)
ARFI elastography
    Interquartile range, m/sec 0.751 - 0.132 - -
    Interquartile range/median 0.423 - 0.145 - -
    Interquartile range/mean 0.903 - 0.644 - -
OR, odds ratio; CI, confidence interval; INR, international normalized ratio; HBV, hepatitis B virus; HBeAg, hepatitis B e antigen; ARFI, acoustic 
radiation force impulse.
Fig. 3. Percentage of nondiscordance and discordance in stages F0–2 and stages F3–4. One-stage discordance was more frequently observed in 
patients with stages F0–2 than those with stages F3–4 (odds ratio, 0.426; 95% confidence interval [CI], 0.187 to 0.969; p=0.040) (A); similarly, 
two-stage discordance was more frequently identified in patients with stages F0–2 than those with stages F3–4 (odds ratio, 0.197; 95% CI, 0.053 
to 0.740; p=0.013) (B). Using the optimal cutoff body mass index (BMI) value, two-stage discordance was more frequently identified in patients 
with BMI ≥25.5 kg/m2 than those with BMI <25.5 kg/m2 (odds ratio, 9.714; 95% CI, 2.381 to 33.329; p<0.001) (C). 
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cally significant positive and negative predictors of two-stage 
discordance, respectively (p=0.006, odds ratio, 1.291, 95% CI, 
1.075 to 1.551; and p=0.016, odds ratio, 0.181, 95% CI, 0.045 
to 0.730, respectively) (Table 3). The two-stage discordance rate 
was significantly lower in patients with stages F3–4 than F0–2 
(5.9% vs 24.1%, respectively; odds ratio, 0.197; 95% CI, 0.053 
to 0.740; p=0.013) (Fig. 3B).
Considering that BMI is positively associated with two-stage 
discordance, further analysis was done by stratifying the study 
population into two groups according to an optimal cutoff BMI 
value which maximize the sum of Se and Sp (25.5 kg/m2 with 
Se of 75.0% and Sp of 76.4%). Two-stage discordance was 
identified in only four of 72 patients (5.6%) with BMI <25.5 
kg/m2, whereas it was noted in 12 of 33 patients (36.4%) with 
BMI ≥25.5 kg/m2 (odds ratio, 9.714; 95% CI, 2.381 to 33.329; 
p<0.001) (Fig. 3C).
DISCUSSION
LS measurement using ARFI elastography was recently in-
troduced and is considered a noninvasive and reproducible tool 
to assess the degree of liver fibrosis.17,25,26 To date, most studies 
that investigated the ability of ARFI elastography to estimate 
the degree of liver fibrosis have been performed in European 
patients with CHC.25,27 In contrast, studies have rarely been 
conducted in patients with CHB, especially in Asian countries, 
where the prevalence of CHB is high.28 In order for the use of 
ARFI elastography to become more widespread, its performance 
should be validated in Asian patients with CHB who have a 
different range of BMIs and viral kinetics from Europeans with 
CHC. Here, we aimed to examine the performance of ARFI elas-
tography in Korean patients with CHB through a multicenter 
study. We found that ARFI elastography exhibited acceptable 
diagnostic accuracy in predicting liver fibrosis. In our study, the 
AUROCs were 0.814 for predicting ≥F2, 0.848 for ≥F3, and 0.752 
for F4, respectively. This performance is quite similar to that of 
a previous Asian study (AUROC, 0.74 for ≥F2 and 0.79 for F4, 
respectively).15 Although further studies of Asian subjects with 
CHB are required, our results might indicate that ARFI elastog-
raphy could be applied in Asian populations as well as Western 
populations.
To date, histologic fibrosis has been the reference standard for 
cross-sectional studies that sought to assure the performance of 
noninvasive tools. However, these comparative methods have 
several problems because certain inherent problems in LB affect 
its accuracy3,4 and cannot reflect the dynamic process of liver 
fibrosis.29 Nevertheless, identification of factors associated with 
discordance between noninvasive surrogates and LB is an im-
portant prerequisite for clarifying potential confounders that can 
influence the diagnostic accuracy of a given noninvasive sur-
rogate. Factors associated with discordance are also important 
for enhancing its performance in assessing intrahepatic fibrotic 
burden by controlling the identified influencing factors. In this 
study, we defined “significant discordance,” based on previous 
studies,23,24,30 as a discordance of at least two stages of fibrosis 
between ARFI elastography and LB, although the definition of 
discordance can potentially bias the results depending on the 
proportion of each fibrosis stage.21 However, we additionally 
analyzed our data using the extended definition of “discordance,” 
or at least one stage of discordance in fibrosis staging between 
ARFI elastography and LB, to minimize the potential bias. We 
found that fibrosis stage F0–2 and BMI are independent factors 
influencing the accuracy of ARFI elastography.
To our knowledge, this is the first study to investigate the 
prevalence of discordance between LB and ARFI elastography 
and its predictors in Asian patients with CHB using a cohort 
from three tertiary medical institutes. In this study, advanced 
fibrosis stage (F3–4) at LB is a predictor of nondiscordance be-
tween LB and ARFI elastography, regardless of whether discor-
dance is defined as a one or two-stage difference, This is similar 
to the results of a previous study regarding the discordance of 
TE and LB.23 Indeed, most discordance in our study was caused 
by overestimation of liver fibrosis by ARFI elastography in pa-
tients with F0–2 (21 cases of 27 histologic F0–1 and 17 of 27 
histologic F2). Although it was hypothesized in a previous study 
regarding the discordance between TE and LB that this high 
prevalence of discordance in those with an early fibrotic burden 
(F0–2) might be due to high ALT levels at this stage of fibrosis,15 
ALT levels were not a predictor of significant discordance in our 
study and were statistically similar between patients with F0–2 
and F3–4. This might be due to the relatively small sample size 
in our study or the relatively low accuracy of ARFI elastography 
in diagnosing early fibrotic burden.31 Although advanced fibro-
sis stage (F3–4) at LB is a predictor of nondiscordance between 
LB and ARFI elastography, its clinical application might be lim-
ited because we cannot obtain histologic data ahead of LB.
In our study, BMI was also selected as a predictor that posi-
tively affects the risk of discordance between ARFI elastography 
and LB, again similar to the result of a previous study regarding 
TE in patients with CHB.32 Using internal cutoff values to cal-
culate discordance, BMI was also selected as the only predictor 
of significant discordance (p=0.018; odds ratio, 1.224; 95% CI, 
1.036 to 1.447). To date, several other studies have also reported 
that a high BMI is significantly related to the risk of measure-
ment failure or low diagnostic accuracy of ARFI elastography, 
as well as TE.12,33 All these support the hypothesis that BMI 
can influence the diagnostic accuracy of noninvasive tools in 
certain ways. Although increased thickness of the thoracic belt 
or an increase in the steatotic burden itself related to higher 
BMIs are potential candidates, the exact mechanism for how 
BMI influences the diagnostic accuracy of ARFI elastography 
is not well understood. There is a paradoxical pitfall that obese 
patients with potential liver fibrosis are most in need of nonin-
vasive tools, but are not able to fully benefit from their accu-
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rate use due to the influence of a high BMI on the accuracy of 
noninvasive tools, such as ARFI elastography. To overcome this 
problem, an XL probe can be used in cases of TE.34 However, 
there are few studies on this issue in ARFI elastography, so fur-
ther study is needed.
The internal cutoff values (1.31 m/sec for ≥F2, 1.81 m/sec for 
≥F3, and 1.98 m/sec for F4) were slightly higher that external 
cutoff values in a previous Asian study15 that proposed 1.13 m/
sec for ≥F2 and 1.81 m/sec for F4, respectively. This disagree-
ment between the internal and external cutoff values might be 
due to differences in the etiology of the liver disease that could 
have influenced the cutoff values (CHB only vs mixed); the het-
erogeneity of the causes of liver diseases is known as one of the 
important factors influencing the diagnostic accuracy of non-
invasive models.35 Although we proposed new cutoff values for 
patients with CHB, larger population based studies are needed to 
validate our results for application in clinical practice.
Several issues still remain unresolved. First, we could not 
investigate the clinical role of ARFI elastography as a non-
invasive monitoring tool to predict dynamic changes in liver 
fibrosis because, due to our cross-sectional design, follow-up 
ARFI elastography was not available in most patients. Second, 
although we identified predictors of patients with discordance, 
it is unclear whether the long-term prognosis of patients with 
discordance differs from that of patients with nondiscordance. 
This should be clearly elucidated in order to use the identified 
influencing factors in clinical practice. Third, in addition to the 
higher prevalence of discordance (64.8% of one-stage discor-
dance), the uneven distribution of fibrosis stage (74.3% of the 
study population had significant fibrosis [≥F2]) may be another 
limitation of our study due to the potential for spectrum bias. 
Finally, the overestimating influence of high ALT level which 
was proposed in several previous studies13,19 was not identified 
in our study. Although the exact reason for this phenomenon 
is not clear, the small sample size of our study might be related 
to this potential false negative result. Further large-scale study 
should be followed to resolve this issue.
In conclusion, advanced fibrosis stage (F3–4) showed a posi-
tive correlation with nondiscordance between LB and ARFI 
elastography. BMI may be another candidate that influences the 
accuracy of ARFI elastography. Future studies should focus on 
methods of enhancing the diagnostic accuracy of ARFI elastog-
raphy using our identified factors in clinical practice.
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Supplementary Fig. 1. Flow dia-
gram of the selected study popula-
tion. A total of 124 consecutive 
patients with chronic hepatitis B 
(CHB) who underwent liver biopsy 
and acoustic radiation force impulse 
(ARFI) elastography were enrolled. 
Nineteen patients were excluded 
based on our exclusion criteria. 
Finally, a total of 105 patients were 
selected for statistical analysis. 
HCC, hepatocellular carcinoma.
124 Patients with CHB who underwent liver
biopsy and ARFI elastography
105 Finally analyzed
19 Exclusion criteria
- History of HCC or another malignancy at the
time of liver biopsy
- Liver biopsy specimen shorter than 10 mm
- Coinfection with HIV or hepatitis C or
hepatitis D virus
- Alcohol ingestion in excess of 40 g/day for
more than 5 years
- Different day between liver biopsy and ARFI
elastography
- Child-Pugh classification B/C
- Evidence of decompensated liver cirrhosis,
including history of variceal bleeding,
ascites, or hepatic encephalopathy
- Previous history of antiviral therapy
Supplementary Table 1. Liver Histology and Corresponding Acoustic 
Radiation Force Impulse Velocity
Stage No. (%) ARFI velocity, m/sec*
0–1 27 (25.7) 1.38±0.37
2 27 (25.7) 1.61±0.42
3 21 (20.0) 2.17±0.59
4 30 (28.6) 2.40±1.18
ARFI, acoustic radiation force impulse.
*ARFI velocity is described as the mean±SD.
Supplementary Table 2. Diagnostic Performances of Acoustic Radiation Force Impulse Velocity
Fibrosis stage AUROC (95% CI) Cutoff values Sensitivity, % Specificity, % NPV, % PPV, % –LR +LR
≥F2 0.814 (0.729 –0.900) 1.31 89.7 63.0 22.2 94.9 0.16 2.42
≥F3 0.848 (0.773 –0.923) 1.81 78.4 78.8 53.7 90.2 0.27 3.7
F4 0.752 (0.656 –0.849) 1.98 66.7 73.3 73.3 66.7 0.45 2.5
AUROC, area under the receiver operating characteristic curve; CI, confidence interval; NPV, negative predictive value; PPV, positive predictive 
value; LR, likelihood ratio.
